The resolution of long-standing investor concerns about KEYTRUDA patent expiration through demonstrated pipeline success has triggered a significant market revaluation of Merck.

"For numerous years, the approaching loss of exclusivity for the blockbuster drug KEYTRUDA posed a substantial burden. For a market fixated on the forthcoming KEYTRUDA revenue gap, this figure serves as a compelling counter-narrative. The significant stock revaluation indicates that Wall Street now confidently endorses this projection."